On January 7, 2021, after market hours, Sarepta announced its gene therapy as a one-time treatment for the rare disorder Duchenne muscular dystrophy failed to show benefits compared with a placebo. Sarepta’s shares dropped almost 49.7%, or $83.95, from closing at $168.95 on January 7, 2021 to open at $85.00 on January 8, 2021.
Attorney Advertising. Prior results do not guarantee a similar outcome.